<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261064</url>
  </required_header>
  <id_info>
    <org_study_id>1235.27</org_study_id>
    <nct_id>NCT02261064</nct_id>
  </id_info>
  <brief_title>Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers</brief_title>
  <official_title>Influence of Food on the Bioavailability of Telmisartan 40 mg/Amlodipine 5 mg Fixed-dose Combination and of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination in Healthy Japanese Male Volunteers (a Phase I, Open-label, Randomised, Single-dose, Two-way Crossover Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the relative bioavailability and pharmacokinetics of the fixed-dose
      combination tablets (telmisartan 40 mg/amlodipine 5 mg and telmisartan 80 mg/amlodipine 5 mg)
      in the fed condition compared with those of the same fixed-dose combination in the fasting
      condition in healthy Japanese male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration of the analyte in plasma (tmax)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant of the analyte in plasma (λz)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of the analyte in the body after po administration (MRTpo)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 56 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Telmisartan/Amlodipine low dose, fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan low dose/Amlodipine fixed-dose combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan/Amlodipine low dose, fasted</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan low dose/Amlodipine fixed-dose combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan/Amlodipine high dose, fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan high dose/Amlodipine fixed-dose combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan/Amlodipine high dose, fasted</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan high dose/Amlodipine fixed-dose combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/Amlodipine low dose</intervention_name>
    <arm_group_label>Telmisartan/Amlodipine low dose, fed</arm_group_label>
    <arm_group_label>Telmisartan/Amlodipine low dose, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/Amlodipine high dose</intervention_name>
    <arm_group_label>Telmisartan/Amlodipine high dose, fed</arm_group_label>
    <arm_group_label>Telmisartan/Amlodipine high dose, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Japanese meal</intervention_name>
    <arm_group_label>Telmisartan/Amlodipine low dose, fed</arm_group_label>
    <arm_group_label>Telmisartan/Amlodipine high dose, fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers without any clinically significant findings and complications
             on the basis of a complete medical history, including the physical examination, vital
             signs (blood pressure, pulse rate, body temperature), 12-lead electrocardiograms
             (ECGs), clinical laboratory tests

          2. Age: ≥20 and Age ≤35 years

          3. Body weight: ≥50 kg

          4. Body mass index (BMI): ≥18.0 and ≤25.0 kg/m2

          5. Signed and dated written informed consent prior to admission to the trial in
             accordance with the Good Clinical Practice (GCP) and the local legislation

        Exclusion Criteria:

          1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, or hormonal disorders

          2. Diseases of the central nervous system (such as epilepsy) or psychiatric or
             neurological disorders

          3. Chronic or relevant acute infections

          4. Any clinical relevant findings in laboratory test results deviating from normal

          5. A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV)
             antibodies, a syphilitic test, or an human immunodeficiency virus (HIV) test

          6. History of surgery of the gastrointestinal tract (except appendectomy)

          7. History of relevant orthostatic hypotension, fainting spells, or blackouts

          8. Known hypersensitivity to any component of the formulation (telmisartan and
             amlodipine), to any other angiotensin II receptor blockers, or to any other
             dihydropyridine compound

          9. Intake of drugs with a long half-life (≥24 hours) within at least 1 month or less than
             10 half-lives of the respective drug before drug administration

         10. Intake of drugs which might reasonably influence the results of the trial on the basis
             of the knowledge at the time of protocol preparation within 7 days before drug
             administration

         11. Participation in another trial with an investigational drug within 4 months or 6
             half-lives of the investigational products before drug administration

         12. Smoker (≥20 cigarettes/day)

         13. Alcohol abuse (60 g or more ethanol/day: e.g., 3 middle-sized bottles of beer, 3 gous
             [equivalent to 540 mL] of sake)

         14. Drug abuse

         15. Blood donation (more than 100 mL within 4 weeks before drug administration)

         16. Excessive physical activities (within 1 week before drug administration)

         17. Intake of alcohol within 2 days before drug administration

         18. Inability to comply with dietary regimen of the study centre

         19. Inability to refrain from smoking during trial days

         20. Subjects judged to be inappropriate by the investigator or a sub-investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

